Listed

Oramed Pharmaceuticals Inc.: Form 10-Q for the period ended Mar 31, 2022

Filed with the SEC on May 12, 2022 and accepted by EDGAR at May 12, 2022, 17:04 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2022-01-01 to 2022-03-31$666.0kus-gaap:Revenues
Research and development3 months2022-01-01 to 2022-03-31$5.8mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2022-01-01 to 2022-03-31−$11.3mus-gaap:OperatingIncomeLoss
Net income3 months2022-01-01 to 2022-03-31−$10.7mus-gaap:NetIncomeLoss
Basic EPS3 months2022-01-01 to 2022-03-31$0.27us-gaap:EarningsPerShareBasic
Operating cash flow3 months2022-01-01 to 2022-03-31−$9.1mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2022-01-01 to 2022-03-31$47.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Current assetsAt period end2022-03-31$143.6mus-gaap:AssetsCurrent
Total assetsAt period end2022-03-31$172.2mus-gaap:Assets
Current liabilitiesAt period end2022-03-31$6.3mus-gaap:LiabilitiesCurrent
Long-term debtAt period end2022-03-31$9.2mus-gaap:LongTermDebt
Shareholders' equityAt period end2022-03-31$162.3mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001213900-22-026004. Last ingested by Listed: Nov 15, 2026, 04:14 ET. Listed shows no prices and gives no investment advice.